Methylphenidate - Pharmacokinetics
Research News and Information

Saturday, November 21, 2009

OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.

30 Jul 2009 Attention-deficit/hyperactivity disorder (ADHD) is one of the most common behavioral disorders in childhood. It continues into adulthood in up to 65% of patients. Methylphenidate (MPH) is one of the most commonly used pharmacological treatments for ... Read more...

Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.

30 May 2009 OBJECTIVE: This study was conducted to quantify the rate and extent of methylphenidate (MPH) absorption from a transdermal system when applied to two different skin sites in pediatric subjects with attention-deficit/hyperactivity disorder (ADHD). ... Read more...

[Drugs for attention deficit hyperactivity disorder]

29 Apr 2009 Quantitative studies have highlighted differences in several drugs approved for use in Spain in the treatment of attention deficit hyperactivity disorder. No clear differences are observed, however, in the case of qualitative studies. The number of ... Read more...

Latest indexed articles for 'Methylphenidate - Pharmacokinetics'

These are the very latest articles for this heading:

• Age-related changes in motor subtle signs among girls and boys with ADHD. 11 Oct 2009
• OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. 30 Jul 2009
• Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. 30 May 2009
• [Drugs for attention deficit hyperactivity disorder] 29 Apr 2009
• Juvenile methylphenidate exposure and factors that influence incentive processing. 15 Apr 2009
• InforMatrix for attention deficit hyperactivity disorder. 30 Mar 2009
• Evolution of stimulants to treat ADHD: transdermal methylphenidate. 30 Dec 2008
• Pharmacokinetics, dose-range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice. 29 Sep 2008
• A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. 30 Aug 2008
• Impact of withdrawal of Ritalin LA in the Western Cape. 30 Jul 2008
• Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. 30 Jul 2008
• Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. 3 Jun 2008
• Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. 30 May 2008
• Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? 30 May 2008
• [Drug-induced psychosis after intake of a modified--release formulation of methylphenidate] 25 May 2008
• Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. 13 May 2008
• Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder. 30 Mar 2008
• [Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part 1: overview and recommendations] 28 Feb 2008
• Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults. 30 Dec 2007
• An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. 30 Dec 2007

See a longer list of these articles.

Technical information about 'Methylphenidate'

Definition: A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE.

Chemical name: 2-Piperidineacetic acid, alpha-phenyl-, methyl ester

Registry Number: 113-45-1

Descriptor UI: D008774

Alternative terms: Methylphenidate; Dexmethylphenidate; Dexmethylphenidate Hydrochloride; Hydrochloride, Dexmethylphenidate; Focalin; Novartis Pharmaceutical Brand of Dexmethylphenidate Hydrochloride; Metadate; Equasym; Celltech Brand of Methylphenidate Hydrochloride; Methylphenidate Hydrochloride; Hydrochloride, Methylphenidate; Phenidylate; Ritalin; Novartis Brand 1 of Methylphenidate Hydrochloride; Ritaline; Cephalon Brand of Methylphenidate Hydrochloride; Ritalin-SR; Ritalin SR; Novartis Brand 2 of Methylphenidate Hydrochloride; Tsentedrin; Centedrin; Daytrana; Methylin; Mallinckrodt Brand of Methylphenidate Hydrochloride;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Dopamine Uptake Inhibitors; Central Nervous System Stimulants;

Tree Number: D02.241.223.601.600; D03.383.621.460;

Online Note: use METHYLPHENIDATE to search PHENIDYLATE 1978-94

History Note: PHENIDYLATE was see METHYLPHENIDATE 1978-94